Cargando…

Omigapil Treatment Decreases Fibrosis and Improves Respiratory Rate in dy(2J) Mouse Model of Congenital Muscular Dystrophy

INTRODUCTION: Congenital muscular dystrophy is a distinct group of diseases presenting with weakness in infancy or childhood and no current therapy. One form, MDC1A, is the result of laminin alpha-2 deficiency and results in significant weakness, respiratory insufficiency and early death. Modificati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Qing, Sali, Arpana, Van der Meulen, Jack, Creeden, Brittany K., Gordish-Dressman, Heather, Rutkowski, Anne, Rayavarapu, Sree, Uaesoontrachoon, Kitipong, Huynh, Tony, Nagaraju, Kanneboyina, Spurney, Christopher F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675144/ https://www.ncbi.nlm.nih.gov/pubmed/23762378 http://dx.doi.org/10.1371/journal.pone.0065468

Ejemplares similares

Glucocorticoid-Treated Mice Are an Inappropriate Positive Control for Long-Term Preclinical Studies in the mdx Mouse
por: Sali, Arpana, et al.
Publicado: (2012)

Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy
por: Willmann, Raffaella, et al.
Publicado: (2017)

Effect of the IL-1 Receptor Antagonist Kineret(®) on Disease Phenotype in mdx Mice
por: Benny Klimek, Margaret E., et al.
Publicado: (2016)

Characterization of Dysferlin Deficient SJL/J Mice to Assess Preclinical Drug Efficacy: Fasudil Exacerbates Muscle Disease Phenotype
por: Rayavarapu, Sree, et al.
Publicado: (2010)

The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice
por: Sali, Arpana, et al.
Publicado: (2013)

Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse
por: Spurney, Christopher F., et al.
Publicado: (2010)

Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice
por: Ziemba, Michael, et al.
Publicado: (2021)

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy
por: Vila, Maria C, et al.
Publicado: (2017)

Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia
por: Duddy, William, et al.
Publicado: (2015)

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects
por: Heier, Christopher R, et al.
Publicado: (2013)

Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies
por: Coley, William, et al.
Publicado: (2012)

Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis
por: Coley, William, et al.
Publicado: (2013)

Membrane Sealant Poloxamer P188 Protects Against Isoproterenol Induced Cardiomyopathy in Dystrophin Deficient Mice
por: Spurney, Christopher F, et al.
Publicado: (2011)

The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse
por: Zhang, Aiping, et al.
Publicado: (2015)

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness
por: Rayavarapu, Sree, et al.
Publicado: (2013)

Elusive sources of variability of dystrophin rescue by exon skipping
por: Vila, Maria Candida, et al.
Publicado: (2015)

Effects of Dantrolene Therapy on Disease Phenotype in Dystrophin Deficient mdx Mice
por: Quinn, James L, et al.
Publicado: (2013)

Skeletal, cardiac, and respiratory muscle function and histopathology in the P448Lneo− mouse model of FKRP-deficient muscular dystrophy
por: Yu, Qing, et al.
Publicado: (2018)

Antioxidants Reduce Muscular Dystrophy in the dy(2J)/dy(2J) Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
por: Harandi, Vahid M., et al.
Publicado: (2020)

Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS).
por: Thangarajh, Mathula, et al.
Publicado: (2018)

Bortezomib Does Not Reduce Muscular Dystrophy in the dy(2J)/dy(2J) Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
por: Körner, Zandra, et al.
Publicado: (2016)

Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020)

Secreted acid sphingomyelinase as a potential gene therapy for limb girdle muscular dystrophy 2B
por: Bittel, Daniel C., et al.
Publicado: (2022)

Mechanism of action and therapeutic route for a muscular dystrophy caused by a genetic defect in lipid metabolism
por: Tavasoli, Mahtab, et al.
Publicado: (2022)

Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
por: Ogundele, Michael, et al.
Publicado: (2021)

Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy
por: Fang, Yuan, et al.
Publicado: (2023)

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
por: Tatem, Kathleen S., et al.
Publicado: (2014)

Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy
por: Heier, Christopher R, et al.
Publicado: (2019)

Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
por: Goemans, Nathalie, et al.
Publicado: (2020)

Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit
por: Sreetama, Sen Chandra, et al.
Publicado: (2018)

Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
por: Hogarth, Marshall W., et al.
Publicado: (2017)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Mitochondrial dysfunction and consequences in calpain-3-deficient muscle
por: Jahnke, Vanessa E., et al.
Publicado: (2020)

Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
por: Pasteuning-Vuhman, S., et al.
Publicado: (2018)

Fibroadipogenic progenitors are responsible for muscle loss in limb girdle muscular dystrophy 2B
por: Hogarth, Marshall W., et al.
Publicado: (2019)

Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019)

VBP15, a Glucocorticoid Analogue, Is Effective at Reducing Allergic Lung Inflammation in Mice
por: Damsker, Jesse M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2safhe437b7su79o807afmh7qn